Dapagliflozin: A new treatment option for Chronic Heart Failure

摘要

Introduction: Heart failure is a global escalating public health issue. Its prevalence increases with age and with other comorbidities like Hypertension, Diabetes mellitus, Obesity, Chronic lung diseases etc. MI, stroke, limb ischaemia have traditionally been considered as long-term complications of DM, but now-a-days heart failure has been recognized as one of the earliest, most common, and most serious cardiovascular disorders in patients with DM. Following its onset, diabetic patients experience marked deterioration, frequent hospitalization and ultimately, death.1 In the recent past, the therapeutic agents which were used to treat DM, were either ineffective (e.g. DPP-4 inhibitors) or harmful (e.g. Thiazolidinediones) in treating heart failure, and therefore, there was a dire need for an effective and safe therapeutic option for diabetic patients with heart failure.